Braeburn is dedicated to transforming the management of opioid use disorder (OUD) to help people begin and sustain their recovery. At Braeburn, we challenge the status quo and champion transformation of the management of OUD. We partner with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential. Our product, BRIXADI, is the first and only weekly and monthly subcutaneous injection for moderate to severe OUD and is the only buprenorphine injectable that utilizes FluidCrystal®* Injection Depot Technology. For more information, visit https://braeburnrx.com/wp-content/uploads/brixadi-prescribing-information.pdf
website: https://braeburnrx.com